Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Haematologica, Vol 92, Issue 1, 139-140 doi:10.3324/haematol.10564
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kolstad, A.
Right arrow Articles by Torfoss, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kolstad, A.
Right arrow Articles by Torfoss, D.

Malignant Lymphomas

Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen

Arne Kolstad*,, Harald Holte*, Alexander Fosså*, Grete Fossum Lauritzsen*, Peter Gaustad°, Dag Torfoss*

* Cancer Clinic, Rikshospitalet-Radiumhospitalet Medical Center, Montebello, N-0310 Oslo, Norway;
° Medical Microbiology Laboratory, Rikshospitalet-Radiumhospitalet Medical Center, Gaustad, N-0027 Oslo, Norway

Correspondence: Arne Kolstad, Stanford University, Division of Oncology, Palo Alto, CA 94305 USA. Phone: international +650.7256456. E-mail: akolstad{at}stanford.edu

We report six cases of Pneumocystis jirovecii pneumonia (PCP) verified by immunoflourescence/polymerase chain reaction of bronchoalveolar fluid among 46 lymphoma patients (13%) who received rituximab-CHOEP-14 at our institution. PCP prophylaxis should be standard management for this group of patients and also considered for patients treated with rituximab-CHOP-14, CHOP-14 or CHOEP-14.




This article has been cited by other articles:


Home page
 JAMAHome page
J. A. Kovacs and H. Masur
Evolving Health Effects of Pneumocystis: One Hundred Years of Progress in Diagnosis and Treatment
JAMA, June 24, 2009; 301(24): 2578 - 2585.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
L. L. Teichmann, M. Woenckhaus, C. Vogel, B. Salzberger, J. Scholmerich, and M. Fleck
Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis
Rheumatology, August 1, 2008; 47(8): 1256 - 1257.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. S. Ahmed and C. F. Wong
Rituximab and nephrotic syndrome: a new therapeutic hope?
Nephrol. Dial. Transplant., January 1, 2008; 23(1): 11 - 17.
[Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2007 by the Ferrata Storti Foundation.